Search Results for 'gemcitabine cisplatin'
-
Search Results
-
Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer – the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
A Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
https://clinicaltrials.gov/ct2/show/NCT03101566
Gavin
A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03086993
Gavin
A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03656536
Gavin
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)
https://clinicaltrials.gov/ct2/show/NCT03875235
Gavin
Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma
A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03656536
Gavin
A Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
https://clinicaltrials.gov/ct2/show/NCT03101566
Gavin
A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03086993
Gavin
A Phase 3, First Line Study of Pemigatinib vs Gemcitabine/Cisplatin in Patients with Cholangiocarcinoma
https://clinicaltrials.gov/ct2/show/NCT03656536
Gavin
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)
https://clinicaltrials.gov/ct2/show/NCT03875235
Gavin
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (TOPAZ-1)
https://clinicaltrials.gov/ct2/show/NCT03875235
Gavin
Hello everyone.
Apologize that my first posting is a questioning, since the ‘Introduction’ board kept asking me to log in even though I already logged in.
My father is a 74-year-old intrahepatic bile duct cancer patient, diagnosed at April 2016, got surgery but have had a relapse after 1 year.
He has underwent 1st-line chemo(cisplatin + gemcitabine) and now having unofficial 2nd-line chemo(cisplatin + xeloda) due to metastases at lung. He has two stents running side-by-side in common hepatic duct for draining bile from left and right major branches, but for unknown reason stents are not working so now has two PTBDs left and right respectively, and they keep total bilirubin level below 1.0.
One month ago I found a clinical trial(NCT03801038) that I think promising and contacted the study manager for participation possibility. As my father(and I) is an international patient we contacted them via email. My father was declined to register the trial that I don’t understand clearly. Here is an excerpt of the reply from study manager.
“Stent and percutaneous bile drain are not absolute contraindications; however, this tells us that your father’s liver is not healthy or functioning appropriately enough to handle the intensive chemotherapy treatment that is required to condition the immune system to then be able to administer TIL. The biggest risk on the trial during treatment is infection given the lymphodepletion (stunting immune system) and having abnormal connections to the biliary tree in the liver can cause life threatening infections such as cholangitis. For these, reasons, it does not sound like your father would be a candidate for this treatment.”
The study manager tells that ‘stent and PTBD are not absolute contraindications’. However, they say they don’t even need to see my father for further examination. Then isn’t it an ‘absolute contraindication’? Do I have wrong understanding of ‘contraindication’?
Could someone help me understand why my father was rejected even without having any absolute contraindications?
Thank you.
Nicolo
A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given with Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) alone in Patients with Intrahepatic Cholangiocarcinoma
